Loading
A phase 2 trial of Fruquintinib, Trifluridine/tipiracil in colorectal cancer, run by Criterium, Inc., now recruiting.
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06992258 by Criterium, Inc., with 120 participants planned, started 2025-10-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Trifluridine/tipiracil, Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Trifluridine/tipiracil, Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Cytotoxic chemotherapy.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Cytotoxic chemotherapy.
Shares Trifluridine/tipiracil, Anti-angiogenic therapy, Cytotoxic chemotherapy, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/